Evidence map›Paper›PMID 37974969›Full record

ArticleRSC medicinal chemistry2023

Selective isoxazolopyrimidine PAT1 (SLC26A6) inhibitors for therapy of intestinal disorders.

Tifany Chu, Joy Karmakar, Peter M Haggie, Joseph-Anthony Tan, Riya Master, Keerthana Ramaswamy, Alan S Verkman, Marc O Anderson, Onur Cil

Open access · greenAbstract read
In one paragraph

Article in RSC medicinal chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Tifany ChuDepartment of Pediatrics, University of California, San Francisco San Francisco CA USA onur.cil@ucsf.edu.
Joy KarmakarDepartment of Pediatrics, University of California, San Francisco San Francisco CA USA onur.cil@ucsf.edu.
Peter M HaggieDepartment of Medicine, University of California, San Francisco San Francisco CA USA.
Joseph-Anthony TanDepartment of Medicine, University of California, San Francisco San Francisco CA USA.
Riya MasterDepartment of Pediatrics, University of California, San Francisco San Francisco CA USA onur.cil@ucsf.edu.
Keerthana RamaswamyDepartment of Pediatrics, University of California, San Francisco San Francisco CA USA onur.cil@ucsf.edu.
Alan S VerkmanDepartment of Medicine, University of California, San Francisco San Francisco CA USA.
Marc O AndersonDepartment of Chemistry and Biochemistry, San Francisco State University San Francisco CA USA.
Onur CilDepartment of Pediatrics, University of California, San Francisco San Francisco CA USA onur.cil@ucsf.edu.ORCID https://orcid.org/0000-0001-5178-0199
University of California, San Francisco · USSan Francisco State University · US

Funding

SynthesisP30DK072517 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI VERKMAN, ALAN S · 2005 to 2022
$18.1M
SLC26A3 (DRA) Inhibitors for Treatment of Hyperoxaluria and NephrolithiasisR01DK126070 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CIL, ONUR · 2020 to 2024
$1.6M
NIDDK NIH HHS P30 DK072517NIDDK NIH HHS R01 DK126070
6 · The paper itself

Abstract

A loss of prosecretory Cl

Identifiers

PMID37974969
PMCPMC10650448
OpenAlexW4386742948

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.